Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 May;113(1):127-34.
doi: 10.1007/s11060-013-1098-2. Epub 2013 Mar 4.

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study

Darren Hargrave  1 , Birgit Geoerger, Didier Frappaz, Torsten Pietsch, Lyle Gesner, Laura Cisar, Aurora Breazna, Andrew Dorman, Ofelia Cruz-Martinez, Jose Luis Fuster, Xavier Rialland, Céline Icher, Pierre Leblond, David Ashley, Giorgio Perilongo, Martin Elliott, Martin English, Niels Clausen, Jacques Grill
Affiliations
Clinical Trial

A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study

Darren Hargrave et al. J Neurooncol. 2013 May.

Abstract

A multicenter, two stage phase II study, investigated irinotecan plus temozolomide in children with newly diagnosed high grade glioma. The primary endpoint was tumor response during a two-cycle treatment window, confirmed by external review committee. Patients received oral temozolomide 100 mg/(m(2) day) (days 1-5) and intravenous irinotecan 10 mg/(m(2) day) (days 1-5 and 8-12) for two 21-day cycles (three cycles for patients exhibiting objective tumor response). Standard treatment was then administered according to local investigator choice. In total 17 patients were enrolled and treated by local investigators. However, central pathology review found three patients did not have a diagnosis of high grade glioma and another four patients did not have evaluable disease according to independent central radiological review. The primary endpoint was based on the first ten evaluable patients as determined by the external review committee. Recruitment was stopped for futility after there were no complete or partial responses during the two-cycle treatment window in the first ten evaluable patients. Five patients had stable disease, and five progressed. Data for secondary endpoints including; time to tumor progression, time to treatment failure, and overall survival is reported. The safety profile of the treatment showed the combination was tolerable with two patients (11.8 %) having grade three nausea, and one (5.9 %) experiencing a grade four neutropenia, leading to permanent discontinuation from adjuvant treatment. Irinotecan plus temozolomide, although well tolerated did not improve outcome over historical controls in this setting.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
    1. Cancer Res. 2001 Jan 1;61(1):53-8 - PubMed
    1. Clin Cancer Res. 2002 Jul;8(7):2202-9 - PubMed
    1. Neuro Oncol. 2002 Apr;4(2):102-8 - PubMed
    1. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed

Publication types

MeSH terms

LinkOut - more resources